Altona Diagnostics
Private Company
Funding information not available
Overview
Altona Diagnostics is a long-established, privately-held German company focused on PCR-based diagnostic solutions. Its core business is the development and commercialization of assays for detecting infectious diseases, with a portfolio that includes CE-IVD kits for clinical use and RUO kits for research. Recent product launches, such as a triplex assay for chikungunya, dengue, and Zika viruses and an HDV RT-PCR kit, demonstrate an active pipeline targeting tropical, emerging, and viral diseases. The company appears to be in a commercial, revenue-generating stage, supported by ongoing hiring across various operational functions.
Technology Platform
PCR and RT-PCR-based assay development for multiplex detection and differentiation of pathogens.
Opportunities
Risk Factors
Competitive Landscape
Altona competes in the crowded molecular diagnostics space against global giants like Roche, Abbott, BioMérieux, and Qiagen, as well as numerous specialized PCR companies. Its differentiation lies in its specific focus on multiplex assays for tropical/emerging pathogens and its position as a long-standing European PCR specialist. Competition is based on assay performance, menu breadth, price, and ease of integration into laboratory workflows.